Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Bioscience Corp. on May 15, 2019. The filing details the entry into material definitive agreements regarding the licensing of the company's patented DehydraTech technology and the announcement of significant results from an animal study conducted on the technology.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on contractual agreements and scientific study results.
Material Changes and Agreements
- Amendment of Original Agreement: Lexaria, Lexaria CanPharm ULC, and Nuka Enterprises, LLC amended an April 2018 Intellectual Property License Agreement. Rights were assigned to CanPharm, and the license for DehydraTech technology (for products with 0.3% or more THC) was expanded to include Michigan, Massachusetts, Illinois, Ohio, and Colorado (for beverages).
- New Definitive Agreement: Nuka Enterprises entered into a 10-year non-exclusive license agreement with Lexaria Hemp Corp. (a wholly-owned subsidiary) for DehydraTech technology used in beverages containing 0.3% or less THC for sale in the United States.
- Fee Structure: Nuka agreed to pay additional annual territory fees for new states and usage fees for products sold in all new territories under both agreements.
Outlook, Management Commentary, and Study Results
Management announced results from an animal study demonstrating that DehydraTech technology facilitates faster delivery and higher absorption of cannabinoids compared to conventional coconut oil and MCT oil formulations. Key findings include:
- Speed of Delivery: CBD was measurable in blood within 2 minutes using DehydraTech, whereas no measurable CBD was found in the MCT formulation group at the same time.
- Concentration Levels: At 15 minutes, CBD blood concentration was 475% higher with DehydraTech; at 60 minutes, it was 319% higher.
- Total Delivery: Over the 60-minute study, the average maximum CBD blood concentration was 334% higher, and the total quantity of CBD delivered was 389% higher compared to the MCT oil formulation.
- Blood-Brain Barrier: The study confirmed DehydraTech outperforms MCT oil by 246% in facilitating CBD delivery across the blood-brain barrier.
Investor Verification Checklist
- Verify the specific terms of the "Definitive Agreement" and "Amending Agreement" regarding territory fees and usage fee percentages.
- Confirm the regulatory status of the expanded territories (Michigan, Massachusetts, Illinois, Ohio, Colorado) for the specific product types mentioned.
- Review the methodology and peer-reviewed status of the animal study to assess the applicability of results to human clinical trials.
- Monitor future filings for financial impact resulting from the new licensing fees and territory expansions.